Literatur
AWMF, Deutsche Krebsgesellschaft, Deutsche Krebshilfe. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms, Version 3.1. 2018; AWMF-Registernr. 032/024OL
Faries MB et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211-22
Leiter U et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019;37(32):3000-8
Grundmann O et al. Sensitivity of Salivary Glands to Radiation from Animal Models to Therapies. J Dent Res. 2009;88(10):894-903
Saiag P et al. Efficacy of hypofractionated radiotherapy (RT) in melanoma patients who failed anti PD-1 monotherapy: Assessing the abscopal effect. Int J Cancer. 2020;147(6):1707-14
Tarhini AA et al. IFN-α in the treatment of melanoma. J Immunol. 2012; 189: 3789-93
Ives NJ et al. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017; 82:171-83
Eggermont AM et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-30
Weber J et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-35
Eggermont AMM et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789-801
Eggermont AM et al. EORTC 1325-MG/ Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow up. J Clin Oncol. 2020;38(suppl_15):Abstr 10000
Majo M et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19(4): 510-20
Long GV et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017; 377(19):1813-23
Hausschild A et al. Long- term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAFV600-mutant melanoma: Five-year analysis of COMBI-AD. J Clin Oncol. 2020; 38(suppl_15):Abstr 10001
Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30
Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-62
Wolchok JD et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377(14):1345-56
Ascierto PA et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019;5(2):187-94
Robert C et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9):1239-51
Larkin J et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Eng J Med. 2019; 381(16):1535-46
Long GV et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631-9
Robert C et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-9
Ascierto PA et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)- mutant melanoma (coBRIM): updated efficacy results from a randomised, doubleblind, phase 3 trial. Lancet Oncol. 2016; 17(9):1248-60
Dummer R et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315-27
Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26
Andtbacka RHI et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780-8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peeken, L., Schultz, E. & Debus, D. Malignes Melanom . Im Fokus Onkologie 24, 23–27 (2021). https://doi.org/10.1007/s15015-020-3353-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15015-020-3353-7